Acer Therapeutics Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AT</div>
ACER -- USA Stock  

USD 3.25  0.10  3.17%

Whilst many millenniums are getting more into healthcare space, it makes sense to sum up Acer Therapeutics against current trends within the economy. As expected, Acer Therapeutics is starting to reaffirm its true potential as retail investors are becoming more and more confident in the future outlook. The company returns are correlated to each other to returns on the market. As market moves up or down, the company is expected to follow. The record of invariable basic indicators of the enterprise connotes a short-term price swing for retail investors of Acer Therapeutics. The upcoming quarterly report is expected on the 17th of March 2021. The stock is currently experiencing an active upward rally.
Published over a month ago
View all stories for Acer Therapeutics | View All Stories
Is Acer Therapeutics (NASDAQ:ACER) outlook still optimistic?
This firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Acer Therapeutics market sentiment investors' perception of the future value of Acer Therapeutics. Let us look at a few aspects of Acer Therapeutics technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Acer Therapeutics. In general, we focus on analyzing Acer Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acer Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Acer Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Acer Therapeutics, we also check how macroeconomic factors affect Acer Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Acer Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Acer Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acer Therapeutics. Your research has to be compared to or analyzed against Acer Therapeutics' peers to derive any actionable benefits. When done correctly, Acer Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Acer Therapeutics.

How does Acer Therapeutics Stands against Peers?

Analyzing Acer Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Acer Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Acer Therapeutics Competition Details

How Acer Therapeutics utilizes its cash?

To perform a cash flow analysis of Acer Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Acer Therapeutics is receiving and how much cash it distributes out in a given period. The Acer Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Acer Therapeutics Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Acer Therapeutics reported last year Net Cash Flow from Operations of (26.56 Million)

Closer look at Acer Therapeutics Mean Deviation

Acer Therapeutics has current Mean Deviation of 2.59. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.

Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.

Mean Deviation 
 = 
SUM(RET DEV) 
 = 
2.59
SUM = Summation notation
RET DEV = Sum of return deviations of Acer Therapeutics
N = Number of calculation points for selected time horizon
Let's now compare Acer Therapeutics Mean Deviation to its closest peers:
ACER
EARS
DTIL
EQ
DYAI
ACER2.5949266712580354
EARS12.51
DTIL4.45
EQ5.38
DYAI2.25

Will Acer Therapeutics latest spike continue?

The semi deviation is down to 2.77 as of today. Acer Therapeutics currently demonstrates below-verage downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.05. However, we do advice investors to further question Acer Therapeutics expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Conclusion on Acer Therapeutics

While many other companies under the biotechnology industry are still a bit expensive, Acer Therapeutics may offer a potential longer-term growth to retail investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Acer Therapeutics as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acer Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Acer Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com